On November 6, 2019 MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) reported presentation of so far unpublished data on tafasitamab, its proprietary key asset and investigational hemato-oncological drug candidate, at the upcoming 61th American Society of Hematology (ASH) (Free ASH Whitepaper) 2019 Annual Meeting, taking place from December 7-10, 2019 in Orlando, Florida (Press release, MorphoSys, NOV 6, 2019, View Source [SID1234550480]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This year, overall four abstracts feature the clinical development of tafasitamab in diffuse large B-cell lymphoma (DLBCL) as well as other blood cancer indications. In addition, three abstracts feature preclinical data.
Abstracts on the clinical development of tafasitamab in DLBCL:
Subgroup analysis from the L-MIND trial, a phase 2 study assessing tafasitamab in combination with lenalidomide in patients with relapsed or refractory DLBCL
Trial in progress update for the First-MIND trial, an open label, randomized study in patients with newly diagnosed DLBCL
Abstracts on the clinical development of tafasitamab in other blood cancer indications:
Results from the COSMOS trial, assessing tafasitamab in combination with idelalisib or venetoclax in patients with relapsed of refractory chronic lymphocytic leukemia (CLL)
Final analysis and long term follow-up of tafasitamab monotherapy in patients with relapsed or refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)
Preclinical abstracts on in vitro studies:
Study investigating gamma delta T cells and allogeneic activated NK cells as effector cells for tafasitamab
Study investigating the influence of tafasitamab on CAR-T cell activity
Study investigating tumor-associated macrophages as effector cells for tafasitamab
"We are excited to present a number of important updates on our investigational compound tafasitamab at this year’s ASH (Free ASH Whitepaper)," said Dr. Malte Peters, Chief Development Officer of MorphoSys AG. "The seven accepted abstracts provide insights into our scientific and clinical activities to evaluate the efficacy and safety of tafasitamab. The data highlight our commitment to patients with high unmet medical needs."
MorphoSys will meet ASH (Free ASH Whitepaper) attendees at the Orange County Convention Center, at Booth #1261.
Details about MorphoSys’s abstracts accepted for presentation at ASH (Free ASH Whitepaper) 2019:
Subgroup analysis from L-MIND, a Phase II Study of Tafafsitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Abstract publication number: 1582
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) – Results from Prospective Clinical Trials: Poster I
Session date and time: Saturday, December 7th, 2019; 9:00am – 7:30pm ET
Poster presentation time: 5:30pm – 7:30pm ET
A Phase Ib, Open-label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-MIND Trial
Abstract publication number: 2877
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) – Results from Prospective Clinical Trials: Poster II
Session date and time: Sunday, December 8th, 2019; 9:00am – 8:00pm ET
Poster presentation time: 6:00 pm – 8:00 pm ET
Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial)
Abstract publication number: 1754
Session: 642. CLL: Therapy, excluding Transplantation: Poster I
Session date and time: Saturday, December 7th, 2019; 9:00am – 7:30pm ET
Poster presentation time: 5:30pm – 7:30pm ET
A Phase IIa, Open-label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma: Long-term Follow-up, Final Analysis
Abstract publication number: 4078
Session: 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas) – Results from Prospective Clinical Trials: Poster III
Session date and time: Monday, December 9th, 2019; 10:00am – 8:00pm ET
Poster presentation time: 6:00 pm – 8:00 pm ET
Targeting of CD19 by Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity In Vitro
Abstract publication number: 2859
Session: 625. Lymphoma: Pre-Clinical-Chemotherapy and Biologic Agents: Poster II
Session date and time: Sunday, December 8th, 2019; 9:00am – 8:00pm ET
Poster presentation time: 6:00 pm – 8:00 pm ET
Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells as Effector Cells for Tafasitamab (MOR208)
Abstract publication number: 3801
Session: 605. Molecular pharmacology drug resistance – lymphoid and other diseases: Poster III
Session date and time: Monday, December 9th, 2019; 10:00am – 8:00pm ET
Poster presentation time: 6:00 pm – 8:00 pm ET
Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide
Abstract publication number: 4064
Session: 625. Lymphoma: Pre-Clinical-Chemotherapy and Biologic Agents: Poster III
Session date and time: Monday, December 9th, 2019; 10:00am – 8:00pm ET
Poster presentation time: 6:00 pm – 8:00 pm ET
The abstracts will also be available online in a supplemental issue of Blood. Additional information, including the abstracts, can be found in the online meeting program of the American Society of Hematology (ASH) (Free ASH Whitepaper).